The terms of the deal for Geneva-based Endosense also allow for up to $161 million in milestone payments, according to a news release. A St. Jude Medical spokeswoman said the acquisition closed on Aug. 16.
According to the company, physicians currently have to estimate the measure of force during such procedures. The use of too little force can lead to additional treatments to treat atrial fibrillation recurrence, while too much force can cause a risk of tissue injury, the company said.
“This transaction significantly accelerates our timeline to providing an irrigated ablation catheter that incorporates force sensing in both international and U.S. markets, and has potential future applications across other St. Jude Medical technology platforms as well,” Frank Callaghan, president of St. Jude Medical's cardiovascular and ablation technologies division, said in the news release.
The company plans to submit its pre-market approval application for the TactiCath technology to the Food and Drug Administration this year.
Follow Jaimy Lee on Twitter: @MHjlee
